Immunotherapies have revolutionized the treatment of cancer, resulting in cures in subsets of cancer patients, yet remain ineffective for the majority of patients. We are developing methods to extend life-saving immunotherapies to all individuals struck by cancer. Our work aims to address the major bottlenecks preventing wider use of immunotherapies and is grounded in first principles: discovering tumor-specific targets using multi-omics approaches and engineering target-specific immune receptors using combined computational and experimental techniques.

 

Our team operates at the dynamic crossroads of genomics, proteomics, immunology, antibody engineering, and computational biology, developing and implementing cutting-edge technologies to safely and effectively treat cancer. We have mapped the landscape of tumor-specific T cell targets across tumors and are generating a pipeline of new therapies for cancer patients in need. We are actively developing technologies to enable personalized immunotherapies for any cancer patient. Our novel class of peptide-centric (PC)-CAR T cells potently eradicate aggressive tumors and are in Phase 1 clinical trials in 2025.